{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:59:58Z","timestamp":1780966798917,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.exer.2026.111078","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:45:38Z","timestamp":1779205538000},"page":"111078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel NRF2 activator designed for an ophthalmic solution"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7943-1126","authenticated-orcid":false,"given":"Tomoyo","family":"Miyabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1674-2696","authenticated-orcid":false,"given":"Yayoi","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8469-6870","authenticated-orcid":false,"given":"Takeshi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2026.111078_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","article-title":"The molecular basis of retinal ganglion cell death in glaucoma","volume":"31","author":"Almasieh","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2026.111078_bib2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ophtha.2014.04.016","article-title":"Nocturnal systemic hypotension increases the risk of glaucoma progression","volume":"121","author":"Charlson","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2026.111078_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.exer.2015.10.009","article-title":"Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye","volume":"145","author":"Chastain","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2026.111078_bib4","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3390\/antiox10091466","article-title":"The effects of two Nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy","volume":"10","author":"Chien","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.exer.2026.111078_bib5","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1021\/acs.jmedchem.6b00228","article-title":"Monoacidic inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery","volume":"59","author":"Davies","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.exer.2026.111078_bib6","doi-asserted-by":"crossref","first-page":"954771","DOI":"10.3389\/fddev.2022.954771","article-title":"Topical ophthalmic administration: can a drug instilled onto the ocular surface exert an effect at the back of the eye?","volume":"2","author":"del Amo","year":"2022","journal-title":"Front. Drug. Deliv."},{"key":"10.1016\/j.exer.2026.111078_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tips.2022.12.003","article-title":"Advances and challenges in therapeutic targeting NRF2","volume":"44","author":"Dinkova-Kostova","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.exer.2026.111078_bib8","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/ph17121579","article-title":"Ocular and plasma pharmacokinetics of sitagliptin eye drops: preclinical data","volume":"17","author":"Hern\u00e1ndez","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.exer.2026.111078_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/jnc.12325","article-title":"Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death","volume":"127","author":"Himori","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.exer.2026.111078_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2025.110511","article-title":"Hypoxia-induced activation of calpain and oxidative stress in mitochondria leads to RGC death in human iPSC-derived retinal organoids","volume":"259","author":"Hirata","year":"2025","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2026.111078_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096481","article-title":"Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits","volume":"9","author":"Kida","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2026.111078_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.phrs.2008.03.004","article-title":"Bromocriptine activates NQO1 via Nrf2-PI3K\/Akt signaling: novel cytoprotective mechanism against oxidative damage","volume":"57","author":"Lim","year":"2008","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.exer.2026.111078_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.7150\/ijbs.25996","article-title":"The Nrf2 signaling in retinal ganglion cells under oxidative stress in ocular neurodegenerative diseases","volume":"14","author":"Liu","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.exer.2026.111078_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229421","article-title":"NFE2L2 activator RS9 protects against corneal epithelial cell damage in dry eye models","volume":"15","author":"Matsuda","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2026.111078_bib15","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.12688\/f1000research.12111.1","article-title":"Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate","volume":"6","author":"Satoh","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.exer.2026.111078_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.112.084269","article-title":"Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model","volume":"84","author":"Shimozono","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.exer.2026.111078_bib17","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/sctm.17-0059","article-title":"Enhanced stem cell differentiation and immunopurification of genome engineered human retinal ganglion cells","volume":"6","author":"Sluch","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.exer.2026.111078_bib18","article-title":"The potential role of nuclear factor erythroid 2-related factor 2 (Nrf2) in glaucoma: a review","volume":"26","author":"Wang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.exer.2026.111078_bib19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.exer.2026.111078_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109006","article-title":"Topical ocular drug delivery systems: innovations for an unmet need","volume":"218","author":"Yang","year":"2022","journal-title":"Exp. Eye Res."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526002344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526002344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:30:41Z","timestamp":1780965041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483526002344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["S0014483526002344"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2026.111078","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel NRF2 activator designed for an ophthalmic solution","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2026.111078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111078"}}